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Abstract 
HSP90 is an abundant protein in Leishmania parasites that plays a major role in the 
parasite survival under stress conditions. Here we found that the HSP90 inhibitor 17-
AAG (≥100 nM 17-AAG) induced cell cycle arrest at G0/G1 in L. infantum and L. 
panamensis promastigotes, and highly potentiated the induction of cell death by an 
apoptotic-like process mediated by the ether phospholipid edelfosine (5-20 μM). These 
data suggest that the combined treatment of 17-AAG and edelfosine might be a novel 
and effective approach of combination therapy in the treatment of leishmaniasis. 
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1. Introduction 
The current therapy of leishmaniasis, caused by the protozoan parasite Leishmania, 
includes a rather small number of drugs and is not satisfactory. The emergence of drug 
resistance and toxicity urges the identification of new targets and drugs in the treatment 
of this disease. 
Heat shock proteins (HSPs) comprise several highly conserved families of 
protein folding facilitators that play important roles in the maintenance of cell 
functionality and in stress cell response, with HSP90 being of particular impact in the 
regulation of key steps in a multitude of biological processes (Queitsch et al., 2002; 
Whitesell and Lindquist, 2005). HSP83, the Leishmania ortholog of the human HSP90, 
is highly and constitutively expressed in Leishmania spp., where represents about 2.8% 
of the total cell protein (Brandau et al., 1995). Amino acid sequence alignment analysis 
shows high level of identity of the HSP90 proteins of L. braziliensis, L. major and L. 
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donovani (~93%), which in turn show ~63% identity with human HSP90 (Silva et al., 
2013). L. infantum JPCM5 HSP83 protein (NCBI Reference Sequence: 
XP_003392729.1) (Peacock et al., 2007) shows 62% identity and 78% similarity with 
human HSP90 (GenBank: AAA36025.1) (Rebbe et al., 1987) by BLAST analysis, thus 
suggesting that Leishmania HSP83 might exert a similar function as human HSP90. In 
mammalian cells, HSP90 is involved in the stabilization and correct folding of a number 
of different client proteins, many of them playing a major role in cell survival, cell 
proliferation, and cancer cell growth (Whitesell and Lindquist, 2005). In this regard, 
HSP90 has become a valuable target in cancer chemotherapy as its inhibition promotes 
proteasomal degradation of client proteins required for tumor cell survival (Whitesell 
and Lindquist, 2005). Despite HSP90 is promiscuous in its action, and therefore caution 
should be taken into account to avoid undesired effects on chemotherapy (Nieto-Miguel 
et al., 2008), a wide number of studies have shown that HSP90 inhibitors enhance the 
cytotoxic action of some anticancer drugs (George et al., 2005; Neckers, 2002). 
Similarly, inhibition of HSP90 in Leishmania parasites using specific inhibitors, such as 
geldanamycin, radicicol and 17-N-allylamino-17-demethoxygeldanamycin (17-AAG, 
tanespimycin) has been shown to affect transformation of promastigotes into rounded 
amastigote-like forms and to kill intracellular amastigotes (Li et al., 2009; Petersen et 
al., 2012; Wiesgigl and Clos, 2001a). These data suggest that HSP90 inhibition might 
be a new therapeutic approach in the treatment of leishmaniasis. 
On the other hand, the ether lipid edelfosine (1-O-octadecyl-2-O-methyl-rac-
glycero-3-phosphocholine), a rather selective antitumor drug that acts at the cell 
membrane level (Gajate et al., 2004; Gajate and Mollinedo, 2007; Mollinedo et al., 
2010a), exerts in vitro antiparasitic activity against different species of Leishmania 
(Azzouz et al., 2006; Azzouz et al., 2005; Croft et al., 2003; Lux et al., 2000). 
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Furthermore, we have recently found following in vitro and in vivo studies that 
edelfosine represents a promising drug against leishmaniasis, killing Leishmania 
parasites through an apoptosis-like process (Varela-M et al., 2012). In our previous 
study (Varela-M et al., 2012), we found striking differences in the sensitivity of 
promastigotes from different species of Leishmania to edelfosine, including sensitive 
promastigotes, such as L. panamensis, and rather resistant ones, such as L. infantum. On 
these grounds, we analyzed here whether the combination of the HSP90 inhibitor 17-
AAG (tanespimycin), currently in clinical trials as an antitumor agent (Katragadda et 
al., 2013; Neckers and Workman, 2012), and edelfosine could improve the 
antileishmanial activity of the ether lipid.  
 
2. Materials and methods 
2.1. Drugs 
Edelfosine was from R. Berchtold (Biochemisches Labor, Bern, Switzerland). Stock 
sterile solution of edelfosine (2 mM) was prepared as previously described (Mollinedo 
et al., 1997) in complete RPMI-1640 culture medium (Invitrogen, Carlsbad, CA), 
supplemented with 10% (v/v) heat-inactivated fetal bovine serum (FBS). 17-AAG was 
purchased from InvivoGen (San Diego, CA). An 8 mM 17-AAG stock solution in 
dimethyl sulfoxide (DMSO) (Sigma, St Louis, MO) was aliquoted and stored at -20°C 
until use. 
 
2.2. Leishmania cells and culture conditions 
The following Leishmania strains were used in this study: L. infantum 
(MCAN/ES/96/BCN150) and L. panamensis (MHOM/CO/87/UA140). Leishmania 
promastigotes were grown in RPMI-1640 culture medium, supplemented with 10% 
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FBS, 2 mM glutamine, 100 units/ml penicillin, and 100 µg/ml streptomycin at 26ºC. 
Promastigotes were treated with the indicated compounds during their logarithmic 
growth phase (1.5 or 2 x 106 parasites/ml) at 26ºC.  
 
2.3. Growth inhibition assay  
The inhibition of promastigote growth was determined by using the XTT (sodium 3,3’-
[1-(phenylaminocarbonyl)-3,4-tetrazolium]-bis (4-methoxy-6-nitro) benzene sulfonic 
acid hydrate) cell proliferation kit (Roche Molecular Biochemicals, Mannheim, 
Germany) as previously described (David-Cordonnier et al., 2005; Varela-M et al., 
2012). Cells were resuspended in FBS-containing RPMI-1640 culture medium (1.5 x 
106 cells/ml) and plated (100 μl/well) in 96-well flat-bottomed microtiter plates at 26ºC, 
in the absence and in the presence of 10 µM 17-AAG. After 17-h incubation at 26ºC, 
the percent of growth inhibition was calculated with respect to untreated controls. 
Measurements were done in triplicate. 
 
2.4. Analysis of apoptosis-like cell death by flow cytometry  
Leishmania spp. promastigotes were treated for different times in the absence and in the 
presence of the indicated concentrations of 17-AAG at 26ºC. Edelfosine was then used 
at the indicated concentrations for 24 h. In combination therapies, 17-AAG was 
preincubated for 1 h before adding edelfosine. Thus, promastigotes were untreated or 
treated with different concentrations of 17-AAG for 1 h, and then incubated in the 
absence or presence of edelfosine for 24 h in combined treatments. Then, parasites were 
pelleted by centrifugation (1000 x g) for 6 min, and analyzed for apoptosis-like DNA 
breakdown by flow cytometry following a protocol previously described (Gajate et al., 
2000). Quantitation of apoptotic-like cells was monitored as the percentage of cells in 
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the sub-G0/G1 region (hypodiploidy) in cell cycle analysis, using a fluorescence-
activated cell sorting (FACS)Calibur flow cytometer (Becton Dickinson, San Jose, CA) 
equipped with a 488 nm argon laser. WinMDI 2.8 software was used for data analysis. 
In addition, photographs of untreated and drug-treated parasites, before starting their 
preparation for flow cytometry assays, were taken using a Zeiss Axioplan microscope 
(Carl Zeiss GmbH, Oberkochen, Germany) at 40X magnification. 
 
3. Results 
3.1. 17-AAG inhibits cell cycle in Leishmania spp. promastigotes 
We found that 10 µM 17-AAG arrested L. infantum and L. panamensis promastigotes at 
the G0/G1 phase of cell cycle, as assessed by flow cytometry (Figs. 1A and 1B), which 
led to a complete growth inhibition (Fig. 1C). Treatment of Leishmania spp. 
promastigotes with 10 µM 17-AAG induced dramatic changes in cell morphology, 
leading to stubby-shaped bodies, rounding-up, and changes in the flagellum (Fig. 2). 
Following a concentration-response analysis (10 nM – 10 µM), we found that 
incubation with ≥100 nM 17-AAG promoted a concentration-dependent cell cycle arrest 
at the G0/G1 phase (Table 1), and morphological changes similar to those described 
above. Removal of 17-AAG by washing off the drug and subsequent reculture of the 
cells in drug-free medium for 3 days allowed a partial recovery of the normal cell cycle 
profile (data not shown). 
 
3.2. 17-AAG pretreatment sensitizes Leishmania spp. parasites to edelfosine-induced 
cell death   
We have recently reported that the ether phospholipid edelfosine induces cell death in 
Leishmania parasites through an apoptosis-like process (Varela-M et al., 2012). Here 
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we found that pretreatment of Leishmania promastigotes with 10 μM 17-AAG highly 
potentiated the anti-Leishmania activity of edelfosine, used at 5 μM in L. panamensis 
and 20 μM in L. infantum. Distinct drug concentrations were initially used because of 
the distinct drug sensitivity of L. panamensis and L. infantum promastigotes as 
previously reported (Varela-M et al., 2012). The anti-Leishmania activity was assessed 
by an increase in the percentage of hypodiploid cells (protozoa at the sub-G0/G1 region 
of cell cycle) (Figs. 3A and 3B), suggesting an apoptosis-like cell death. In order to 
determine the lowest concentration of 17-AAG able to potentiate the anti-Leishmania 
activity of edelfosine, we used the HSP90 inhibitor in the range 10 nM-10 μM. The 
potentiation of edelfosine-induced apoptosis was detected after incubation with 17-
AAG at a concentration ≥100 nM and at 5 μM edelfosine (Table 2). Lower 
concentrations of 17-AAG or edelfosine were not effective. Incubation with 10 nM - 10 
μM 17-AAG at 26ºC did not promote apoptosis in both Leishmania species, but the 
percentage of hypodiploid cells was increased following incubation with 5 µM 
edelfosine, which per se was unable to elicit cell death in the absence of HSP90 
inhibitor in L. infantum promastigotes or induced a weak cell death response in L. 
panamensis promastigotes (Table 2). These results suggest that 17-AAG facilitates the 
induction of apoptosis-like cell death mediated by edelfosine.  
 
4. Discussion 
The data reported here indicate that the combined treatment of 17-AAG and edelfosine 
largely potentiates the killing activity of the ether phospholipid edelfosine on 
Leishmania spp. promastigotes. Interestingly, L. infantum promastigotes were 
previously reported rather resistant to the action of the ether lipid, requiring drug 
concentrations of ≥20 μM (Varela-M et al., 2012), but here we have found that 
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pretreatment with 17-AAG turned L. infantum promastigotes into edelfosine-sensitive 
protozoa. Our present data show that L. infantum promastigotes become sensitive to the 
combined use of 17-AAG (≥100 nM) and 5 μM edelfosine, thus lowering the edelfosine 
concentration required to induce cell death in this Leishmania species. Our results 
indicate that both L. panamensis and L. infantum promastigotes become sensitive to 
similar concentrations of edelfosine, thus suggesting that incubation with the HSP90 
inhibitor decreases the differences in drug resistance between both Leishmania species. 
The data reported here indicate that 17-AAG preincubation increases the edelfosine-
mediated cytotoxic response in L. panamensis promastigotes and turns L. infantum 
promastigotes into sensitive cells, thus suggesting that HSP90 inhibition facilitates or 
leads to a higher upregulation of the cell death response triggered by edelfosine in 
Leishmania promastigotes. On these grounds, 17-AAG sensitizes Leishmania parasites 
to edelfosine, and it might be envisaged that HSP90 inhibition could be an interesting 
way to potentiate antiparasitic therapy. Because 17-AAG is currently in clinical trials 
(Katragadda et al., 2013; Neckers and Workman, 2012; Usmani et al., 2009)], and 
preclinical assays indicate a rather lack of significant toxicity for edelfosine (Gajate et 
al., 2004; Mollinedo et al., 2010a; Mollinedo et al., 2010b; Mollinedo et al., 2009), our 
data suggest that the combination of 17-AAG and edelfosine could be a new approach 
to treat leishmaniasis that warrants further investigation. 
 Previous studies have shown that HSP90 inhibitors geldanamycin and radicicol 
induce growth arrest and differentiation from the L. donovani promastigote to the 
amastigote stage, suggesting that disturbances in HSP90 homeostasis are a signal for the 
onset of stage differentiation in Leishmania parasites (Wiesgigl and Clos, 2001a; 
Wiesgigl and Clos, 2001b). On the other hand, Li et al. (Li et al., 2009) have previously 
shown that incubation of L. donovani promastigotes with the HSP90 inhibitor 
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geldanamycin at 37ºC in pH 5.5 induced cell cycle arrest at G0/G1 followed by an 
apoptosis-like cell death. In relation to the above observations, we also found that the 
HSP90 inhibitor 17-AAG induced morphological changes that could be similar to 
amastigote conversion, as well as cell cycle arrest at G0/G1. We have previously found 
that L. infantum axenic amastigotes are more sensitive to edelfosine than the 
promastigote forms (Varela-M et al., 2012), and therefore it is tempting to suggest that 
HSP90 inhibition could mimic stage conversion and thereby might increase edelfosine 
sensitivity of L. infantum parasites. Similarly to the data reported in L. donovani 
promastigotes by Li et al. (Li et al., 2009), we found here that 17-AAG incubation leads 
to cell cycle arrest, but, unlike what was found in L.donovani parasites, we were unable 
to detect apoptosis-like cell death after 24 h treatment in both L. panamensis and L. 
infantum promastigotes. A putative explanation for this apparent discrepancy lies in the 
different experimental conditions used, that is incubation at 37ºC in pH 5.5 in L. 
donovani promastigotes (Li et al., 2009) and incubation at 26ºC and pH 7.5 in the data 
herein reported. Furthermore, HSP90 inhibitors have been reported to increase 
upregulation of HSPs (Wiesgigl and Clos, 2001a) that could prevent cell death in the 
absence of the ether lipid.    
 Taken together, our present and previous data (Varela-M et al., 2012) indicate 
that 17-AAG leads to cell cycle arrest and edelfosine promotes an apoptosis-like 
response in Leishmania spp. The cell cycle arrest, inhibiting cell proliferation, might 
decrease the probability to render drug resistance, thus potentiating the cell death 
response triggered by a cytotoxic drug. This could represent a good example of 
combination therapy, bringing together both cytostatic and proapoptotic agents in the 
treatment of leishmaniasis. HSP90 protects and stabilizes a wide number of proteins 
involved in cell survival (Whitesell and Lindquist, 2005). Thus, it might be envisaged 
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that inhibition of HSP90 leads to the degradation of some critical proteins in 
Leishmania survival that would facilitate the action of a proapoptotic agent, such as 
edelfosine. Our results reported here indicate that the combined addition of 17-AAG 
and edelfosine is effective against Leishmania parasites causing visceral (L. infantum) 
and cutaneous (L. panamensis) leishmaniasis. Interestingly, a recent study has shown 
that 17-AAG is able to inhibit growth of L. amazonensis (IC50, ~65 nM), L. major (IC50, 
~80 nM) and L. infantum (IC50, ~169 nM) axenic amastigotes, and reduced intracellular 
L. amazonensis viability in infected macrophages in a dose- and time-dependent manner 
(Petersen et al., 2012). Our data indicate that 17-AAG at a similar concentration range 
(100 nM) arrests cell cycle and facilitates the killing activity of edelfosine on 
Leishmania promastigotes, further supporting a beneficial action of 17-AAG as a 
putative drug in anti-Leishmania therapy by affecting both Leishmania promastigotes 
and amastigotes. However, because the assays reported here were conducted with 
promastigote cells, further experiments are needed to evaluate the feasibility of the 
combined therapy in amastigote cells and host conditions. Furthermore, both 17-AAG 
(Petersen et al., 2012) and edelfosine (Mollinedo et al., 2009) have been reported to 
lower or inhibit inflammation that, in turn, could be beneficial on leishmaniasis 
treatment. This inhibitory action would be of particular importance in the treatment of 
cutaneous and muco-cutaneous leishmaniasis, which are characterized by an intense 
inflammatory response causing severe tissue destruction (Lopez Kostka et al., 2009; 
Tasew et al., 2010). 
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FIGURE LEGENDS 
Figure 1. 17-AAG inhibits proliferation of Leishmania promastigotes. (A) Dot-plot 
histogram representing the distinct phases of cell cycle in control untreated L. infantum 
(upper) and L. panamensis (lower) promastigotes, and after treatment with 10 µM 17-
AAG for 17 h by flow cytometry analysis. (B) Profiles of cell cycle analysis from the 
above dot-plot histograms showing the distinct cell cycle phases of control untreated 
(black) L. infantum and L. panamensis promastigotes, and after treatment with 10 µM 
17-AAG for 17 h (red). The position of the G0/G1 phase is indicated. (C) L. panamensis 
and L. infantum promastigotes were incubated in the absence and in the presence of 10 
µM 17-AAG for 17 h and then the percentage of cell growth inhibition was determined 
by the XTT method. Representative experiments of three performed are shown.    
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Figure 2. 17-AAG induces changes in Leishmania promastigote morphology. L. 
infantum and L. panamensis promastigotes, untreated (Control) and treated with 10 µM 
17-AAG for 17 h were analyzed for changes in cell morphology. Red arrows show 
different forms of parasite morphology. 
 
Figure 3. 17-AAG pretreatment potentiates the antileishmanial activity of 
edelfosine. L. infantum (A) and L. panamensis (B) promastigotes were untreated 
(Control) or treated with 10 µM 17-AAG for 1 h, and then incubated in the absence or 
presence of edelfosine (EDLF; 5 µM for L. panamensis; 20 µM for L. infantum) for 24 
h. Apoptosis-like cell death was then quantitated as the percentage of promastigotes in 
the sub-G0/G1 region by flow cytometry, and indicated in each histogram. The positions 
of the G0/G1 and sub-G0/G1 regions are indicated. Representative experiments of three 
performed are shown. 
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Table 1. Induction of G0/G1 arrest in L. panamensis and L. infantum promastigotes 
upon 17-AAG treatment. 
 
 % cells in G0/G1
17-AAG L. panamensis L. infantum 
No addition 65.7 ± 2.3 66.1 ± 3.7 
17-AAG (10 nM) 65.8 ± 3.1 66.3 ± 3.9 
17-AAG (100 nM) 78.3 ± 2.9 76.2 ± 3.3 
17-AAG (1 µM) 82.4 ± 3.0 78.3 ± 3.2 
17-AAG (10 µM) 82.6 ± 4.2 79.5 ± 4.8 
 
The percentages of cells at G0/G1 were determined by flow cytometry upon incubation 
with the indicated concentrations of 17-AAG for 24 h at 26ºC. Data are means ± SD of 
three independent experiments. 
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Table 2. Induction of apoptosis-like cell death in L. panamensis and L. infantum 
promastigotes by the combined treatment with 17-AAG and edelfosine. 
 
 % cell death (sub-G0/G1) 
HSP inhibitor L. panamensis L. infantum 
 + Edelfosine (5 µM) + Edelfosine (5 µM) 
No addition 19.6 ± 5.3   3.2 ± 1.1 
17-AAG (10 nM) 19.8 ± 3.5   3.5 ± 1.4 
17-AAG (100 nM) 38.3 ± 4.5 27.4 ± 3.9 
17-AAG (1 µM) 44.2 ± 6.1 30.4 ± 4.3 
17-AAG (10 µM) 46.3 ± 7.2 33.5 ± 5.2 
 
Promastigotes were untreated or treated with the indicated concentrations of 17-AAG 
for 1 h, and then incubated in the presence of 5 µM edelfosine for 24 h at 26ºC. 
Apoptosis-like cell death was determined by flow cytometry as the percentage of cells 
at the sub-G0/G1 region. Cells incubated only with 17-AAG for the same period of time 
did not induce a significant apoptosis-like cell death response. Data are means ± SD of 
three independent experiments. 
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